Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at BTIG Research

Key Points

• BTIG Research has initiated coverage on Monopar Therapeutics (NASDAQ:MNPR), assigning a "buy" rating and setting a price target of $87.00, indicating a potential upside of 109.74% from its previous close.
• Several analysts have provided ratings for Monopar Therapeutics, with one "Strong Buy," seven "Buy," and one "Hold," resulting in an average rating of "Buy" and a consensus target price of $71.75.
• Monopar Therapeutics reported an EPS of ($0.35) for the latest quarter, beating analysts’ expectations, while its shares were recently down 6.2% to open at $41.48.

BTIG Research began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Free Report) in a research report report published on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $87.00 price objective on the stock.

MNPR has been the topic of a number of other reports. HC Wainwright began coverage on Monopar Therapeutics in a report on Tuesday, August 26th. They set a "buy" rating and a $70.00 target price on the stock. Wall Street Zen upgraded Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald restated an "overweight" rating and issued a $74.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. Raymond James Financial began coverage on Monopar Therapeutics in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating and a $80.00 price target for the company. Finally, Chardan Capital restated a "buy" rating and issued a $60.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $71.75.

Monopar Therapeutics Stock Up 3.3%

Shares of MNPR stock traded up $1.55 during trading on Tuesday, reaching $49.22. 22,352 shares of the company's stock were exchanged, compared to its average volume of 39,662. The stock has a market capitalization of $303.69 million, a PE ratio of -14.78 and a beta of 1.20. Monopar Therapeutics has a twelve month low of $3.33 and a twelve month high of $54.30. The firm's fifty day moving average price is $39.06 and its 200-day moving average price is $36.76.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12. As a group, analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Activity

In other news, Director Kim R. Tsuchimoto sold 8,904 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the completion of the sale, the director directly owned 11,486 shares in the company, valued at approximately $459,440. This represents a 43.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the director owned 5,173 shares of the company's stock, valued at approximately $206,920. The trade was a 76.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 42,504 shares of company stock worth $1,700,160. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently modified their holdings of MNPR. Janus Henderson Group PLC bought a new stake in shares of Monopar Therapeutics during the 4th quarter valued at $23,435,000. Point72 Asset Management L.P. bought a new stake in shares of Monopar Therapeutics during the 4th quarter worth $3,694,000. Gerber LLC bought a new stake in shares of Monopar Therapeutics during the 1st quarter worth $204,000. AlphaQuest LLC bought a new stake in shares of Monopar Therapeutics during the 1st quarter worth $44,000. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Monopar Therapeutics during the 1st quarter worth $2,257,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.